Acasti's CaPre, which is a mix of DHA and EPA, would be competing with other already FDA approved omega-3 products that also contain a mix of DHA and EPA (i.e. Lovaza, Lovaza generics, Epanova). Amarin's Vascepa is unique in that it is only EPA. There is some worry that products that contain high dose DHA will raise LDL-C, whereas EPA is more or less LDL-C neutral. Acasti's CaPre is expected to complete its Phase 3 safety/TG lowering efficacy trials by end of next year. By this time, Epanova's STRENGTH CVOT trial will likely have reported results. If positive, Acasti may be able to ride on the coat tails with their version of a DHA/EPA mix. However, Acasti may need to do their own CVOT trial, which wouldn't complete until several years from now. 

BearDownAZ